ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NRXS Neuraxis Inc

2.97
-0.03 (-1.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neuraxis Inc AMEX:NRXS AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.03 -1.00% 2.97 3.01 2.92 3.01 4,358 21:03:12

NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

27/02/2024 4:00pm

GlobeNewswire Inc.


Neuraxis (AMEX:NRXS)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Neuraxis Charts.

NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that President and Chief Executive Officer Brian Carrico and Chief Medical Officer Dr. Adrian Miranda, will participate in the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12, 2024.

NeurAxis will give a corporate presentation on Tuesday, March 12, 2024, at 8:40 am ET and host investor 1x1 meetings, which can be requested through Oppenheimer. To access the live webcast, please visit the investors page of the NeurAxis website. The webcast will also be available for replay on NeurAxis’ investor relations website.

About NeurAxis, Inc.NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

Contacts:

CompanyNeurAxis, Inc.info@neuraxis.com

Investor RelationsGilmartin GroupIR@neuraxis.com

1 Year Neuraxis Chart

1 Year Neuraxis Chart

1 Month Neuraxis Chart

1 Month Neuraxis Chart

Your Recent History

Delayed Upgrade Clock